FAQs on Suicidality
What is suicidality?
What is Medication Related Suicidality (MRS)?
Suicidality refers to suicidal ideation and suicide-related behaviors including completed suicide. Suicidal ideation means thoughts related to suicide and suicide plans. Suicide related behaviors include:
- completed suicide: self-inflicted death with intention to die,
- suicidal attempts: self-inflicted potentially harmful behavior without fatal issue but with intention to die,
- self harm: deliberate self-inflicted potentially harmful act regardless of motive.
Suicide is one of the ten leading causes for deaths worldwide (7), contributing 1.5% of all deaths. Approximately 1 million people die due to suicide each year (19, 20).
Risk of suicidal ideation increases rapidly during adolescence and young adulthood and stabilizes in early midlife (9). The greatest risk for suicidal attempts is in adolescence and early adulthood. The prevalence rates in adolescents are reported cross-nationally to be 19.8-24.0% for suicidal ideation, and 3.1% - 8.8% for suicidal attempts (9).
Suicide is the second cause of death among young people, after accidents. The rates of suicide vary according to age; in childhood and early adolescence suicide is rare but suicide rates increase in adolescents and young adulthood. The latest mean worldwide annual rates of suicide per 100 000 were 0.5 for females and 0.9 for males among 5-14-year-olds, and 12.0 for females and 14.2 for males among 15-24-year-olds, respectively (12). Males generally outnumber females in completed suicide, but suicide attempts are more frequent in females.
What conditions or circumstances increase the risk of suicidal ideation
Medication-Related Suicidality (MRS) is defined as any suicide-related symptoms that are reported during the period of treatment with a drug. Generally they apply to worsening of suicidal ideation or new-onset suicidal ideation.
Symptoms include suicidal ideation, suicidal plans and suicidal behaviours and sometimes also extend to non-suicidal self-harm. Mechanisms of MRS are unknown.
A small proportion of children, adolescents and young adults develop MRS with antidepressants, although these drugs generally improve both depressive symptoms and suicidal ideation and behaviors.
What are the warning signs of suicidality?
Depression is one of the major risk factors of suicidal ideation or behaviors. Depression can occur in episodes or as a chronic condition (dysthymia). Recurrent depressive episodes are a feature of depressive disorder and bipolar disorder.
Other conditions heighten the risk of suicidality: anxiety disorders, eating disorders, substance abuse, psychotic disorders and behavioral disorders.
Previous suicide attempts, adverse life circumstances, impulsivity, physical illness, exposure to suicide through media or peers, also increase suicidality.
What should you do if you are worried about suicidality in a friend or relative?
- Behavioral signs
- Statements such as «Life is not worth living», «I would rather be dead»…
- Withdrawal from family, friends, activities
- Giving away possessions, writing a will
- Impulsive acts, risk-taking or self-destructive behavior
- Drug or alcohol use
- Emotional signs
- Feelings of sadness, hopelessness
- Emotional lability or dullness
- Humiliation, anger, guilt, anxiety
What can you do to cope with suicidal thoughts?
- Suicidal signs or statements are to be taken seriously,
- Potential concerns about suicidality should be addressed openly,
- Show emotional availability, be willing to listen, let the child/adolescent know you are concerned,
- Encourage and guide the access to professional help,
- Share your concerns,
- Secure the environment (ensure the person has no access to lethal means),
- Do not: judge, provoke, challenge, be intrusive, ignore
What are the warning signs of depression?
- Get professional help
- Avoid staying alone
- Talk to someone
- Avoid alcohol and drugs
- Stay away from lethal means
- Keep in mind that suicidal ideation and depression are temporary states
Are suicidal ideation, attempts and completed suicide related?
Depression manifests itself through sadness or irritability persisting over long periods (more than 2 weeks) and lasting the major part of the day.
Children and adolescents with depression often have a negative view of themselves (“I’m a loser”), of their social relations (“Nobody understands me”), and of the future (“I’ll never succeed in my projects”). They may be overanxious or bored and emotionless.
They tend to abandon activities and projects they used to find pleasant, refuse to meet their friends. Appetite and sleep are generally altered during depression (they may increase or diminish). Depressed youth generally find it hard to concentrate and engage in school tasks.
Severe depression is associated with intense hopelessness, incapacity to fulfill simple everyday activities and can lead to delusional ideas of ruinand disaster.
Is self-harm related to suicidality?
Suicidal ideation and behaviours can occur both independently and together. The majority of individuals who report suicidal ideation will not try to commit suicide (2). Research across 17 countries has suggested that those who have suicidal ideations have the conditional probability of 29% of ever making a suicide attempt (10). However, attempt increases to 56% for those who do have suicidal ideation and have formulated a plan, but without this plan only 15.4% are likely to attempt suicide (10). The majority of these transitions will occur within the first year of the onset of suicidal ideation (9).
In patients having attempted suicide, 24,5 % will commit another suicidal attempt in the next seven years (4). The risk of suicide in the year following a suicidal attempt is 30 to 200 times higher in comparison with the general population and increases with the number of suicidal attempts, particularly in women (5, 6).
What are the main risk factors of suicidality?
The progression from suicidal ideation to self-harm and then to suicide is by no means absolute. However of those patients who present to hospital with self-harm, around 7% will have completed suicide over a 9 year period of follow-up (11).
The suicide rate appears to be higher amongst those patients who abscond from medical care or who took precautions against discovery (1, 15).
Assessment of suicidality in general
Primary risk factors are associated with high individual risk and are likely targets for therapeutic interventions.
Main primary risk factors are: familial and personal antecedents of suicidal behavior, presence of a psychiatric disorder (mainly depressive disorders and disruptive behaviors), substance use such as repeated acute alcohol intake , the communication of suicidal intent, high impulsivity, high hopelessness (sub-clinical depressive symptoms), presence of a chronic physical illness.
Secondary risk factors are identified in the community and are only partially modifiable; they comprise early loss of a parent, social isolation, unemployment or financial problems, severe adverse life events, being actor or victim of violence.
Tertiary risk factors are statistically associated with suicidal risk but carry a low individual predictive value: age (adolescence and old age), male gender, vulnerability periods (summer, premenstrual period in women).
What is medication-related suicidality?
Patients presenting with suicidal ideation or following a suicide attempt should be assessed at three levels: presence of risk factors, immediacy of suicidal risk and dangerousness of the suicidal means. The immediacy of suicidal risk involves the existence of a suicidal scenario and is rated high if the suicidal plan is precise and concrete, moderate if the plan is imprecise and low in the absence of a scenario.
The absence of alternative for the patient also contributes to the immediacy of risk. Assessment of suicidal means refers to lethality and accessibility of the considered suicide method. Suicidality is generally assessed through clinical interview, eventually completed by questionnaires.
Screening procedures have been developed to identify at-risk children and adolescents in order to offer prevention services. These include self-report measures such as the Columbia Suicide Screen (13), the Suicide Risk Screen and the Suicidal Ideation Questionnaire – Junior (SIQ-Jr) (16).
Universal screening in school settings for example carry the risk of identifying false positives and the issue of follow-up of subjects with positive screens; screening in at-risk groups (children/adolescents in emergency departments, in primary care) is an important issue that also calls for outcome assessments.
What are the mechanisms of medication-related suicidality?
The term ‘Medication-Related Suicidality’ (MRS) is a reported adverse event and is defined as any suicide-related symptoms that are reported during the period of treatment with the drug. Symptoms include suicidal ideation, suicidal plans and suicidal behaviours and sometimes also extend to non-suicidal self-harm.
How can medication-related suicidality be assessed?
The mechanisms involved in increased suicidal ideation and behaviour during treatment are unknown. It has been proposed that medication may induce behavioural activation, including anxiety, irritability, agitation, and insomnia, which would facilitate suicidality, presumably mainly in the first weeks of treatment.
Analyses of community clinical practice databases show conflicting results: some have indeed indicated that the rate of suicidal behaviour is highest in the first month of treatment, and especially during the first nine days (8) but in other analyses the rate was actually the highest in the month prior to starting antidepressant medication with a gradual decline during treatment (3).
Time patterns of suicide attempts in clinical populations show highest rates of suicide attempts in the month before treatment and next highest in the month after starting treatment and decrease afterwards; these time patterns have been shown in adult outpatients with both medications and psychotherapy.
Most suicidal events in the antidepressant trials conducted in children and adolescents occurred in the context of persistent depression and insufficient improvement, without evidence of medication-induced behavioral activation as a precursor (19).
What are the expected improvements in assessing MRS with the STOP project?
Assessment of suicidality in relation to drugs is difficult in particular in children and adolescents because of a number of reasons:
- Assessment procedures of suicidality developed in adults may not be appropriate for younger people (e.g. differences in self-assessment, ability to communicate emotions, abstract thinking)
- Suicidality related to pharmacological treatment may be different from suicidality related to disease.
- Notification and recording of suicidality is variable across clinical trials.
Why should I (or my child) participate in the STOP study?
It is the aim of the STOP project to create a multidimensional assessment and monitoring tool to detect and follow-up suicidal ideas and behaviors that could be implemented in clinical practice and in clinical trials.
This assessment will be based on two classifications: the classification of suicide related thoughts and behavior (17) and the Columbia Classification Algorithm of suicidal assessment (C-CASA) (14).
The output of the STOP assessment is a computer generated classification of suicidality. This comprehensive assessment of suicidality and related individual and environmental variables (moderators and mediators of suicidality) will contribute to a better understanding of the specific characteristics of medication-related suicidality.
Once standardised, the STOP classification could be used for pharmacovigilance and in epidemiological, observational and registration trials.
How do I participate in the study?
Your participation in the STOP study will help to increase our knowledge about suicidality and MRS. Specifically, you will help us to set up better assessments so that suicidality can be identified and treated quickly. Your participation will lead to a better understanding of the risk factors and mechanisms underlying suicidal ideation and behaviour.
By participating in the STOP study you will have the opportunity to meet clinicians and researchers from our academic expert teams. Their goal is to optimize treatments and follow up monitoring for children and adolescents with mental or physical conditions, to make those treatments more secure.
As a participant, you will be informed about the STOP study progress and will have access to updated research and therapeutic issues related to suicidality and MRS.
The STOP project will recruit children and adolescents followed up for depression, asthma and for conduct disorder. Before these studies can be started, we will also recruit children treated in the STOP centres (for different conditions) to help us finalizing a questionnaire that will then be used to develop our web-based assessment.
To participate in a given study of the STOP project, yourself or your parents can contact us to obtain detailed information about the different studies.